Notice
This is not the latest version of this item. The latest version can be found at: https://scientiasalut.gencat.cat/handle/11351/6527.2
dc.contributor | Departament de Salut |
dc.contributor.author | Servei Català de la Salut. Gerència del Medicament |
dc.date.accessioned | 2021-11-11T09:45:37Z |
dc.date.available | 2021-11-11T09:45:37Z |
dc.date.issued | 2021-11 |
dc.identifier.citation | Servei Català de la Salut. Gerència del Medicament. Medicaments biosimilars. Barcelona: Servei Català de la Salut; 2021. |
dc.identifier.uri | https://hdl.handle.net/11351/6527 |
dc.description | Biosimilar drugs; Biological drugs; Usage |
dc.description.abstract | A drug is considered biological when it contains one or more active ingredients synthesized or derived from a biological source. Its complexity is very variable and can go from proteins already existing in the human body, such as insulin or growth hormone, to biotechnological drugs designed using molecular biology techniques with genetic manipulation (monoclonal antibodies, gene therapy, among others) |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments - Equivalència terapèutica |
dc.subject | Biotecnologia farmacèutica |
dc.subject.mesh | Biosimilar Pharmaceuticals |
dc.subject.mesh | /administration & dosage |
dc.title | Medicaments biosimilars |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | fármacos biosimilares |
dc.subject.decs | /administración & dosificación |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |